CBIO — Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 41
- Website: https://crescentbiopharma.com
Latest SEC filings for CBIO
- S-8 — 2026-09-18
- 8-K — 2026-08-26
- 8-K — 2026-08-07
- 10-Q — 2026-08-07
- 8-K — 2026-07-30
- 10-Q — 2026-07-30
- 424B3 — 2026-07-30
- POS AM — 2026-07-30
- 8-K — 2026-07-16
- 8-K/A — 2026-07-15
Latest CBIO news
- — Crescent Biopharma Announces Grants of Inducement Awards (globenewswire.com)
- — Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
- — Crescent Biopharma Announces Grants of Inducement Awards (globenewswire.com)
Educational tool only — not investment advice.